Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 3:S1556-0864(25)00819-6.
doi: 10.1016/j.jtho.2025.06.028. Online ahead of print.

50 Years of Progress in NSCLC: A New Fellow's Guide in the Clinic

Jarushka Naidoo  1 , Abesh Niroula  2 , Dipesh Uprety  3 , Matthew Smeltzer  4 , Nicole Geissen  5 , Raymond U Osarogiagbon  6 , Mari Mino-Kenudson  7 , Yasushi Yatabe  8 , Kristin Higgins  9 , Aakash Desai  10 , Karen L Reckamp  11 , Jessica Jiyeong Lin  7 , Stephen V Liu  12 , Fiona Hegi-Johnson Franzcr  13 , Nagashree Seetharamu  14 , David Harpole  15 , Martin J Edelman  16 ; IASLC Communications Committee
Affiliations
Review

50 Years of Progress in NSCLC: A New Fellow's Guide in the Clinic

Jarushka Naidoo et al. J Thorac Oncol. .

Abstract

In the past 50 years, we have seen a dramatic evolution in thoracic oncology. We have gone from a time of limited understanding of the biology of lung cancer, no demonstrated benefits for screening, and marginal benefits from therapy to an era of molecular profiling, survival benefits from low-dose computed tomography screening, and a steadily expanding list of therapeutic options. Coupled with these advances have been substantial improvements in approaches related to supportive care and end of life. In this state-of-the-art article, the Communications Committee of the International Association for the Study of Lung Cancer presents a comprehensive summary of how some of the major questions in lung cancer were addressed during the last 50 years: from prevention to staging, screening, diagnostics, therapeutics, and supportive care. This is intended to serve as a "survival guide" for new standards in lung cancer care aimed at clinicians and other interested stakeholders, which places these current standards of care in the context of progress in the last 50 years.

Keywords: 50 Years; Non–small cell lung cancer; Progress; Thoracic Oncology.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr. Naidoo reports receiving institutional grant funding from AstraZeneca, Bristol Myers Squibb, Mirati, Amgen, Pfizer, Takeda, and Roche/Genentech; receiving consulting and honoraria from AstraZeneca, Bristol Myers Squibb, Mirati, Amgen, Pfizer, Takeda, Regeneron, Roche/Genentech, Elevation Oncology, AbbVie, Kaledio Biosciences, Gilead, NGM Pharmaceuticals, Regeneron, Daiichi Sankyo, Summit Therapeutics, Zymeworks, and the Irish Cancer Society; serving on the data safety monitoring boards from AstraZeneca and Bristol Myers Squibb; and serving on the steering committees for AstraZeneca, Bristol Myers Squibb, Summit Therapeutics, Zymeworks, and GlaxosmithKline. Dr. Uprety reports receiving consulting fees for Daiichi Sankyo, AstraZeneca, Sanofi, Jazz Pharmaceuticals, Eli Lilly, Nuvation Bio, and Pfizer. Dr. Geissen reports receiving consulting fees from Intuitive Surgical; honoraria from AstraZeneca and Primeinc; and support for attending meetings from ASCO. Dr. Osarogiagbon reports receiving consulting fees for AstraZeneca, Median Technologies, and GE Healthcare; receiving honoraria from AstraZeneca; having patents from US Patent Office: Lymph node specimen collection kit and method for lymph node examination; and having uncompensated leadership roles with IASLC, Lungevity Scientific Advisory Board, SWOG Cancer Research Network, Lung Cancer foundation of America, G02 Foundation, and the National Lung Cancer Roundtable (steering committees). Dr. Mino-Kenudsen reports receiving consulting fees from AstraZeneca, Boehringer Ingelheim, Innate, Pfizer, Bristol Myers Squibb, AbbVie, Roche, and Daiichi Sankyo and honoraria from Sanofi. Dr. Yatabe reports receiving institutional research funding from Merck Biopharma, Chugai-Pharma, Konica-Minolta REALM, Optieum Biotechnologies, and Eizai; receiving consulting fees from AstraZeneca, Merck Sharp & Dohme, AbbVie, Novartis, Amgen, Daiichi Sankyo, Janssen Pharma, Konica-Minolta REALM; and receiving honoraria from Merck Sharp & Dohme, Chugai-Pharma, AstraZeneca, Merck Biopharma, Novartis, Amgen, Daiichi Sankyo, and Thermo Fisher Science. Dr. Higgins reports receiving consulting for AstraZeneca, Regeneron, and Daiichi Sankyo; receiving support for meeting travel from AstraZeneca; and having leadership (uncompensated) from RTOG Foundation, NRG Oncology Board of Directors. Dr. Desai reports receiving grant funding from Lung Cancer Research Foundation, LUNGevity Foundation, Novellia, and Robert Winn Career Development Grant, and receiving honoraria from Sanofi, Amgen, Foundation Medicine, AstraZeneca, Janssen Oncology, Merus, AbbVie, Catalyst Pharmaceuticals, Merck, Eli Lilly, Daiichi Sankyo, and Regeneron. Dr. Reckamp reports receiving institutional grant funding from Genentech, Blueprint, Daiichi Sankyo, Elevation Oncology, and Johnson & Johnson; and receiving consulting fees from AstraZeneca, Genentech, GlaxoSmithKline, Immunity Bio, Johnson & Johnson, Merus, Novartis, Novocure, and Pfizer. Dr. Lin reports receiving institutional grant funding from Turning Point Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche/Genentech, Linnaeus Therapeutics, Bristol Myers Squibb, Nuvalent, and Novartis; receiving consulting fees from Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, AnHeart Therapeutics, Takeda, CLaiM Therapeutics, Ellipses, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Yuhan, Merus, Regeneron, Pfizer, Roche, Gilead, Janssen, Nuvation Bio, Eli Lilly, AstraZeneca, Gilead, and Turning Point Therapeutics; receiving support for meeting attendance and travel from Pfizer, Takeda, Bristol Myers Squibb, and Merus; and serving on steering committees of Nuvalent, Bristol Myers Squibb, and Genentech. Dr. Liu reports receiving support for this manuscript from AbbVie, Alkermes, AstraZeneca, BioNTech, Bristol Myers Squibb, Cogent Biosciences, Duality, Elevation Oncology, Ellipses, Genentech, Gilead, Medilink, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma, RAPT, Synthekine, and SystImmune; and receiving consulting fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Gilead, GlaxoSmithKline, Guardant Health, Johnson & Johnson, Jazz Pharmaceuticals, Lilly, Merck, Merus, Mirati, Natera, Novartis, OSE Immunotherapeutics, Pfizer, Regeneron, Revolution Medicines, Takeda, and Yuhan. Dr. Hegi-Johnson reports receiving institutional grant funding from AstraZeneca, Telix, and ImaginAb; receiving honoraria from ImaginAb; and having leadership (uncompensated) from IASLC and the TransTasman Radiation Oncology Group. Dr. Seetharamu reports receiving institutional grant funding for Beigene, Mirati, Teligene, Amgen, Genentech, and Bristol Myers Squibb; and serving on the advisory boards for Amgen, Genentech, Boehringer Ingelheim, Jazz, Array Pharma, Regeneron, and Coherus. Dr. Harpole reports receiving consulting for AstraZeneca. Dr. Edelman reports receiving institutional grant funding from Novartis, MBRACE, and Merck; receiving consulting fees and honoraria from Amgen, Catalyst, Jazz, Boehringer Ingelheim, Coherus, Harpoon, Bioalta, GE Healthcare, and American Journal of Managed Care; serving on the data safety monitoring boards from AstraZeneca, Sana, Pfizer, Seagen, AnHeart, Bristol Myers Squibb, and Takeda; having stocks from Creatv Microtech; and having uncompensated leadership of Lung Cancer Foundation of America and American Radium Society. The remaining authors declare no conflict of interest.

LinkOut - more resources